A comparison of the biodistribution and biokinetics of 99mTc-anti-CD66 mAb BW 250/183 and 99mTc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy

  • Inga BuchmannEmail author
  • Thomas Kull
  • Gerhard Glatting
  • Donald Bunjes
  • Geoffrey Hale
  • Jorg Kotzerke
  • Dirk Rattat
  • Hartmut Dohner
  • Sven N. Reske
Original Article


Radioimmunotherapy (RIT) with radiolabelled monoclonal antibodies (mAbs) is an effective method of achieving myeloablation in leukaemia patients prior to stem cell transplantation (SCT). We wished to compare the approaches of specific binding to leukaemic blasts and non-specific binding to benign red marrow cells, which results in a myeloablative "cross-fire" effect. Therefore, we prospectively evaluated the biodistribution and biokinetics of the anti-CD45 mAb YTH 24.5 and the anti-CD66 mAb BW 250/183 with regard to their suitability for myeloablative RIT. The red marrow selective anti-CD66 mAb BW 250/183 (IgG1) binds to normal granulopoietic cells. In contrast, the anti-CD45 mAb YTH 24.5 (IgG2b) binds to 85–90% of acute leukaemic blasts and almost all haematopoietic white cells. Patients with leukaemic blast infiltration of the marrow <25% and assigned for RIT and SCT were included. Twelve patients (eight male, four female; median age 46±7 years) with AML (5), CML (5) or ALL (2) were examined. Both mAbs were labelled with technetium-99m. Within 48 h, 906±209 MBq 99mTc-anti-CD66 mAb and 760±331 MBq 99mTc-anti-CD45 mAb were injected consecutively. Scintigraphic and urinary measurements were performed 1, 2, 4 and 24 h after injection. Serum activities were evaluated 2, 5, 10, 15, 30 and 60 min and 2, 4 and 24 h after injection. Compared with the anti-CD45 mAb, the anti-CD66 mAb showed an approximately fourfold higher accumulation in the red marrow, a 2.5-fold lower accumulation in the liver and similar accumulation in the kidneys. The serum activity (% of the injected dose) initially decreased faster for the anti-CD45 mAb but was similar for the two mAbs 24 h after injection: 3.3%±1.2% (anti-CD66 mAb) and 2.4%±1.1% (anti-CD45 mAb). The cumulated urinary excretion was 17%±6.6% (anti-CD66 mAb) and 27.3%±7.9% (anti-CD45 mAb) 24 h after application. In these patients with low tumour load, the anti-CD66 mAb BW 250/183 showed more favourable properties in terms of biodistribution and pharmacokinetics. Thus, it appears superior to anti-CD45 mAb YTH 24.5 in selectively increasing the marrow dose and avoiding extramedullary organ toxicity.


Radioimmunotherapy Leukaemia Conditioning Myeloablation Anti-granulocyte 



We thank Bettina Mahren for excellent radiochemical labelling and quality control. Further thanks are due to Michael Landmann for data management.


  1. 1.
    Applebaum FR. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997; 24:114–123.Google Scholar
  2. 2.
    Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens [see comments]. Blood 1990; 76:1867–1871.Google Scholar
  3. 3.
    Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77:1660–1665.Google Scholar
  4. 4.
    Bunjes D, Buchmann I, Duncker C, et al. Re-188-labeled anti-CD 66 (a,b,c,e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukaemia or myelodysplastic syndrome: results of a phase I–II study. Blood 2001; 98:565–572.Google Scholar
  5. 5.
    Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med 2001; 28:807–815.Google Scholar
  6. 6.
    Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative Radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation. Cancer Biotherapy Radiopharm 2002; 17:151–163.Google Scholar
  7. 7.
    Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I–anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94:1237–1247.Google Scholar
  8. 8.
    Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122–1131.Google Scholar
  9. 9.
    Schubiger PA, Hasler PH, Novak-Hofer I, Blauenstein P. Assessment of the binding properties of Granuloszint. Eur J Nucl Med 1989; 15:605–608.Google Scholar
  10. 10.
    Hanenberg H, Baumann M, Quentin I, et al. Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin. Leukemia 1994; 8:2127–2133.Google Scholar
  11. 11.
    Boccuni P, Di Noto R, Lo Pardo C, et al. CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of CD10+ early-B-cell malignancies. Tissue Antigens 1998; 52:1–8.Google Scholar
  12. 12.
    Noworolska A, Harlozinska A, Buchegger F, Lawinska B, Richter R. Expression of nonspecific cross-reacting antigen species in myeloid leukemic patients and healthy subjects. Blut 1989; 58:69–73.Google Scholar
  13. 13.
    Bordessoule D, Jones M, Gatter KC, Mason DY. Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67. Br J Haematol 1993; 83:370–383.Google Scholar
  14. 14.
    Reske SN, Karstens JH, Gloeckner W, et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet 1989; 1:299–301.Google Scholar
  15. 15.
    Bindon CI, Hale G, Clark M, Waldmann H. Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis. Transplantation 1985; 40:538–544.Google Scholar
  16. 16.
    Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985; 134:3056–3061.Google Scholar
  17. 17.
    Kotzerke J, Glatting G, Seitz U, et al. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of188Re- and 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med 2000; 41:531–537.Google Scholar
  18. 18.
    Seitz U, Neumaier B, Glatting G, Kotzerke J, Bunjes D, Reske SN. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med 1999; 26:1265–1273.Google Scholar
  19. 19.
    Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72:77–89.Google Scholar
  20. 20.
    Miklos K, Tolnay M, Bazin H, Medgyesi GA. Rat IgG subclasses mediating binding and phagocytosis of target cells by homologous macrophages. Mol Immunol 1993; 30:1273–1278.Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Inga Buchmann
    • 1
    • 4
    Email author
  • Thomas Kull
    • 1
  • Gerhard Glatting
    • 1
  • Donald Bunjes
    • 2
  • Geoffrey Hale
    • 3
  • Jorg Kotzerke
    • 1
  • Dirk Rattat
    • 1
  • Hartmut Dohner
    • 2
  • Sven N. Reske
    • 1
  1. 1.Department of Nuclear MedicineUniversity HospitalUlmGermany
  2. 2.Department of HematologyUniversity HospitalUlmGermany
  3. 3.Sir William Dunn School of PathologyOxfordUK
  4. 4.Klinik und Poliklinik für Nuklearmedizin, Gebäude 210Johannes-Gutenberg-Universität MainzMainzGermany

Personalised recommendations